Uniunea Europeană - franceză - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucémie, lymphocytaire, chronique, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Uniunea Europeană - franceză - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agents antinéoplasiques - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - valsartan - comprimé - 80 mg - composition pour un comprimé > valsartan : 80 mg - groupe antagonistes de l'angiotensine ii, non associés

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - valsartan - comprimé - 40 mg - composition pour un comprimé > valsartan : 40 mg - groupe antagonistes de l'angiotensine ii, non associés

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - valsartan - comprimé - 320 mg - composition pour un comprimé > valsartan : 320 mg - groupe antagonistes de l'angiotensine ii, non associés

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - valsartan - comprimé - 160 mg - composition pour un comprimé > valsartan : 160 mg - groupe antagonistes de l'angiotensine ii, non associés

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

wockhardt uk limited - losartan - comprimé - 45,8 mg - composition pour un comprimé > losartan : 45,8 mg . sous forme de : losartan potassique 50 mg - antagonistes de l'angiotensine ii, non associés.

Franța - franceză - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

wockhardt uk limited - losartan - comprimé - 91,6 mg - composition pour un comprimé > losartan : 91,6 mg . sous forme de : losartan potassique 100 mg - antagonistes de l'angiotensine ii, non associés.

Canada - franceză - Health Canada

imclone, llc - cétuximab - solution - 2mg - cétuximab 2mg - antineoplastic agents